PleoPharma, Inc. to Showcase Innovations at Centri Capital Conference in NYC PleoPharma, Inc. will make a significant presentation at the Centri Capital Conference in New York, highlighting their focus on cannabis health treatment.

PleoPharma, Inc. to Showcase Innovations at Centri Capital Conference in NYC #United_States #New_York #PleoPharma #PP-01 #Cannabis_Use_Disorder

PleoPharma, Inc. Secures $36 Million to Combat Cannabis Withdrawal Issues PleoPharma, Inc. finalizes a $36 million Series B financing round to enhance treatments for cannabis-related health issues amidst rising addiction rates.

PleoPharma, Inc. Secures $36 Million to Combat Cannabis Withdrawal Issues #United_States #Phoenixville #PleoPharma #PP-01 #Cannabis_Use_Disorder

PleoPharma, Inc. Unveils Promising Results in Cannabis Withdrawal Study at Major Conference PleoPharma, Inc. shared positive findings from their cannabis withdrawal syndrome clinical trial, highlighting the potential for their investigational drug to aid those with cannabis use disorder.

PleoPharma, Inc. Unveils Promising Results in Cannabis Withdrawal Study at Major Conference #United_States #New_Orleans #Clinical_Trial #PleoPharma #Cannabis_Use_Disorder

PleoPharma, Inc. Secures New Patent to Enhance Sleep Quality for Cannabis Users PleoPharma, Inc. has successfully secured a new patent aimed at treating sleep disturbances caused by cannabis withdrawal, significantly improving the quality of life for affected patients.

PleoPharma, Inc. Secures New Patent to Enhance Sleep Quality for Cannabis Users #USA #Phoenixville #Sleep_Quality #PleoPharma #Cannabis_Use_Disorder

FDA Fast Tracks PleoPharma's Drug to Combat Cannabis Withdrawal Symptoms PleoPharma, Inc. has received Fast Track designation from the FDA for its drug PP-01, aimed at easing cannabis withdrawal symptoms, marking a significant advancement for patients.

FDA Fast Tracks PleoPharma's Drug to Combat Cannabis Withdrawal Symptoms #USA #FDA_Fast_Track #Phoenixville #PleoPharma #PP-01